Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.16
+0.73005.87%
Post-market: 13.210.0524+0.40%19:56 EDT
Volume:7.07M
Turnover:93.15M
Market Cap:10.50B
PE:-11.77
High:13.53
Open:12.69
Low:12.57
Close:12.43
52wk High:30.05
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.98
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:16.66
PE(LYR):-9.11

Loading ...

Summit Therapeutics COO/CFO Manmeet Soni acquires 50,000 common shares worth $722,250

Reuters
·
Jun 05

Summit Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 05

Stock Track | Summit Therapeutics Soars 5.03% in After-Hours on Positive Lung Cancer Drug Trial Results

Stock Track
·
Jun 02

Assessing Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III And Phase II Trial Results

Simply Wall St.
·
Jun 02

Summit Therapeutics Shares Fall 10%, Reversing Premarket Gains

THOMSON REUTERS
·
Jun 01

Stock Track | Summit Therapeutics Plummets 7.41% Intraday Amid Investor Skepticism Over Lung Cancer Drug Data

Stock Track
·
Jun 01

Stock Track | Summit Therapeutics Plunges 5.25% in Pre-Market Amid Investor Skepticism Over Lung Cancer Drug Data

Stock Track
·
Jun 01

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Dow Jones
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

TIPRANKS
·
Jun 01

Summit Therapeutics Shares Rise 4.1% Premarket After Co's Lung Cancer Drug With China-Based Partner Shows 15% Higher Survival Rate Than Rival's

THOMSON REUTERS
·
Jun 01

Summit Therapeutics Says Ivonescimab Improves Survival Over Tislelizumab in Phase III Lung Cancer Trial

MT Newswires Live
·
Jun 01

Stock Track | Summit Therapeutics Soars 9.06% in Pre-market on Positive Lung Cancer Drug Trial Results

Stock Track
·
Jun 01

Stock Track | Summit Therapeutics Soars 11.46% on Positive Ivonescimab Lung Cancer Trial Results

Stock Track
·
Jun 01

Summit Therapeutics posts HARMONi-6 ASCO 2026 plenary slides on ivonescimab in squamous NSCLC

Reuters
·
Jun 01

Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial

TIPRANKS
·
May 31

Summit Therapeutics presents new results from AK112-206 trial

TIPRANKS
·
May 31

CORRECTED-Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31)

Reuters
·
May 31

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

MT Newswires Live
·
May 28

Assessing Summit Therapeutics (SMMT) Valuation As Ivonescimab Development Draws Fresh Investor Attention

Simply Wall St.
·
May 24